Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.16 USD | 0.00% | -6.09% | -30.55% |
Business Summary
Number of employees: 536
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Small Molecule and Protein Therapeutics
100.0
%
| 271 | 100.0 % | 331 | 100.0 % | +22.37% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
87.0
%
| - | - | 288 | 87.0 % | - |
Non-United States
11.4
%
| - | - | 38 | 11.4 % | - |
Global
1.6
%
| 271 | 100.0 % | 5 | 1.6 % | -98.00% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/07/01 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 02/20/02 |
Ryan Arnold
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/19/20 |
Philip George
PRN | Corporate Officer/Principal | - | 01/22/01 |
Corporate Officer/Principal | - | 01/15/01 | |
Charles Gayer
PRN | Corporate Officer/Principal | 53 | 01/15/01 |
Human Resources Officer | - | 01/18/01 | |
Salisa Hauptmann
LAW | General Counsel | - | 01/21/01 |
Corporate Officer/Principal | 61 | 01/23/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 27/20/27 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 01/07/01 |
Director/Board Member | 60 | 26/21/26 | |
Stephen Aselage
BRD | Director/Board Member | 73 | 04/19/04 |
Director/Board Member | 69 | 10/11/10 | |
Nancy Hutson
CHM | Chairman | 74 | 20/12/20 |
Helen Thackray
CTO | Chief Tech/Sci/R&D Officer | 55 | 20/19/20 |
Steven Galson
BRD | Director/Board Member | 67 | 01/21/01 |
Theresa Heggie
BRD | Director/Board Member | 63 | 03/18/03 |
Amy McKee
BRD | Director/Board Member | 52 | 20/21/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 206,330,603 | 199,798,093 ( 96.83 %) | 0 | 96.83 % |
Company contact information
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 200
27703-8457, Durham
+919 859 1302
http://www.biocryst.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.55% | 858M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- BCRX Stock
- Company BioCryst Pharmaceuticals, Inc.